Oncolytics Biotech (ONCY) Liabilities and Shareholders Equity (2009 - 2026)

Oncolytics Biotech (ONCY) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $7.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 47.53% year-over-year to $7.6 million; the TTM figure through Dec 2025 stood at $46.7 million (down 42.72% YoY), while the FY2025 annual figure was $7.6 million, down 48.58% from the prior year.
• Liabilities and Shareholders Equity retreated to $7.6 million in Q4 2025 per ONCY's latest filing, from $10.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $45.8 million in Q2 2021 and bottomed at $7.6 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $26.6 million across 5 years, with a median of $26.8 million in 2022.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity surged 38.16% — and 2024, when it plunged 49.32%.
• Oncolytics Biotech's Liabilities and Shareholders Equity stood at $36.4 million in 2021, then dropped by 24.44% to $27.5 million in 2022, then increased by 3.67% to $28.5 million in 2023, then slumped by 49.32% to $14.5 million in 2024, then sank by 47.53% to $7.6 million in 2025.
• Business Quant data shows ONCY's Liabilities and Shareholders Equity at $7.6 million in Q4 2025, $10.9 million in Q3 2025, and $14.4 million in Q2 2025.